Get the latest news, insights, and market updates on ESLA (Estrella Immunopharma, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
EMERYVILLE, Calif., December 04, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its review of safety data from the Phase I dose escalation portion of the STARLIGHT-1 trial. Based on the favorable safety profile observed, the DSMB recomme Dec 4, 2025 - $ESLA
Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either?
Royalty Management Holding Corp. and Estrella Immunopharma had the most significant moves on Monday on Barchart’s Top 100 Stocks to Buy, moving up 51 spots. Should you buy either penny stock? If you’re a risk-averse investor, the answer’s obvious. Nov 4, 2025 - $ESLA
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
EMERYVILLE, Calif., November 03, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the successful completion of the second dose cohort in Phase I portion of its STARLIGHT-1 Phase I/II clinical trial of EB103, a CD19-redirected ARTEMIS® T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin’s Lympho Nov 3, 2025 - $ESLA
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
EMERYVILLE, Calif., October 06, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, announces that, as previously disclosed in its Current Report on Form 8-K filed on September 29, 2025, the Company has regained compliance with the listing requirements of The Nasdaq Stock Market LLC ("Nasdaq"). This confirmation follows the Co Oct 6, 2025 - $ESLA
Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
EMERYVILLE, Calif., June 05, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) Jun 5, 2025 - $ESLA
Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing
EMERYVILLE, Calif., June 03, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that on May 30, 2025, it entered into a securities purchase agreement (the "Purchase Agreement") for a private investment in public equity ("PIPE") financing that is expected to result in approximately $3.35 million in gross procee Jun 3, 2025 - $ESLA
Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkin’s Lymphomas
EMERYVILLE, Calif., May 29, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that the first patient has been dosed in the second cohort of its dose escalation study of Phase I/II STARLIGHT-1 trial for EB103, a CD19-redirected ARTEMIS® T-cell therapy to treat patients with Advanced B-Cell Non-Hodgkin’s Lympho May 29, 2025 - $ESLA
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners
EMERYVILLE, Calif., March 05, 2025--Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that CB Capital Partners has initiated coverage on the Company with a Buy rating and a price target of $14.00. Mar 5, 2025 - $ESLA
Estrella Immunopharma completes first dose cohort in STARLIGHT trial
Estrella Immunopharma (ESLA) announced the successful completion of the first dose cohort in its ongoing STARLIGHT-1 Phase I/II clinical trial. Following a review of safety and efficacy data, the Data and Safety Monitoring Board has approved the initiation of the second dose cohort, which will administer 5M receptor-positive T cells per kilogram of body weight of EB103 CD19-Redirected ARTEMIS T-cell therapy. Published first on TheFly – the ultimate source for real-time, market-moving breaking fi Feb 22, 2025 - $ESLA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple